SILVER SPRING, MD — Unanimously disappointed with the end point used to determine clinical benefit, advisors to the US Food and Drug Administration (FDA) agreed the Sentinel Cerebral Protection System ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

Please provide your email address to receive an email when new articles are posted on . Routine cerebral embolic protection did not reduce stroke in patients undergoing transcatheter aortic valve ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window NEW YORK CITY -- ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

WASHINGTON, DC—An exploratory analysis of the PROTECTED TAVR trial suggests that use of the Sentinel cerebral embolic protection system (Boston Scientific) during TAVI had a greater impact in patients ...

Emboline has secured $20 million for its embolic protection system, designed to minimize stroke risk associated with transcatheter aortic valve replacement procedures. The Santa Cruz, CA-based company ...

TCT 319: Short -Term Clinical Effect of Cerebral Embolic Protection Device Following Transcatheter Aortic-Valve Replacement in Korea Population: The Sentinel Registry (Sentinel) Receive the the latest ...

Emboline expects that its technology designed to reduce stroke risk during structural heart procedures will launch in the US and Europe later this year.

CHICAGO -- Routine use of devices to prevent cerebral emboli during transcatheter aortic valve implantation (TAVI) did not prevent strokes, a large randomized trial showed. Incidence of stroke within ...